These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28395515)

  • 21. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
    Shikdar S; Totton D; Turco T; Rachshtut M
    Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
    Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
    Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bendamustine: inadequate or outdated data.
    Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
    Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
    Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.
    Cheung EM; Edenfield WJ; Mattar B; Anthony SP; Mutch PJ; Chanas B; Smith M; Hepner A
    J Clin Pharmacol; 2017 Nov; 57(11):1400-1408. PubMed ID: 28561902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypersensitivity reactions and drug fever by bendamustine: a case report of three patients.
    Barbarroja-Escudero J; Sanchez-Gonzalez MJ; Antolin-Amerigo D; Rodriguez-Rodriguez M; Alvarez-Mon M
    Allergol Int; 2015 Jan; 64(1):109-11. PubMed ID: 25572568
    [No Abstract]   [Full Text] [Related]  

  • 31. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.
    Czuczman MS; Kahanic S; Forero A; Davis G; Munteanu M; Van Den Neste E; Offner F; Bron D; Quick D; Fowler N
    Ann Hematol; 2015 Apr; 94(4):633-41. PubMed ID: 25630297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired Gitelman Syndrome Secondary to Bendamustine Use.
    Rogers A; Gandhi P; Bautista J; Tang J
    R I Med J (2013); 2018 Nov; 101(9):36-38. PubMed ID: 30384518
    [No Abstract]   [Full Text] [Related]  

  • 33. Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
    Lalic H; Aurer I; Batinic D; Visnjic D; Smoljo T; Babic A
    Oncol Rep; 2022 Jun; 47(6):. PubMed ID: 35506458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
    Elsoueidi R; Mulat A; Mourad H
    J Oncol Pharm Pract; 2014 Aug; 20(4):309-11. PubMed ID: 24847047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
    Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies.
    Korycka-Wołowiec A; Robak T
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1455-68. PubMed ID: 22970741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single centre study of using bendamustine in the treatment of B-cell malignancies.
    Osmani AH; Masood N
    J Pak Med Assoc; 2013 Jun; 63(6):702-6. PubMed ID: 23901668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
    Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
    Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
    Laurenti L; Innocenti I; Autore F; Vannata B; Efremov DG; Ciolli S; Del Poeta G; Mauro FR; Cortelezzi A; Borza PA; Ghio F; Mondello P; Murru R; Gozzetti A; Cariccio MR; Piccirillo N; Boncompagni R; Cantonetti M; Principe MI; Reda G; Bongarzoni V; Cervetti G; Pitini V; Foà R; Sica S; D'Arena G
    Leuk Res; 2015 Oct; 39(10):1066-70. PubMed ID: 26307523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.